Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pieper, D. R.
Right arrow Articles by Sawaya, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pieper, D. R.
Right arrow Articles by Sawaya, R. E.

Annals of Surgical Oncology, Vol 4, Issue 6 481-490, Copyright © 1997 by Society of Surgical Oncology

ARTICLES

Role of surgery in the treatment of brain metastases in patients with breast cancer

D. R. Pieper, K. R. Hess and R. E. Sawaya
Department of Neurosurgery, Baylor College of Medicine, Houston, Texas, USA.

BACKGROUND: Patients whose brain metastases from breast cancer are treated nonsurgically have a median length of survival ranging from 2.5 to 7.5 months, and a median time to recurrence ranging from 2 to 5 months. Patients treated with radiotherapy have a median length of survival ranging from 3 to 4 months. Those treated with chemotherapy have a median length of survival ranging from 5.5 to 7.5 months. METHODS: We conducted a retrospective analysis on 63 patients treated over a 10-year period. Only patients who underwent surgery for nonrecurrent brain metastases were studied. Sixty-one patients (97%) underwent surgery within 2 weeks of diagnosis of the brain metastases. RESULTS: The median length of survival was 16 months (95% confidence interval [CI] 11 to 22 months), and the 5-year survival rate was 17% (CI 9% to 29%). Brain metastases recurred in 27 patients at a median interval of 15 months (CI 12 to 24 months). Eleven patients had local recurrence, 10 had distal recurrence, and seven developed leptomeningeal disease. Significant prognosticators of length of survival were age (p = 0.011), menopause status (p = 0.10), postoperative radiotherapy (p = 0.054), preoperative neurologic status (p = 0.011), and preoperative systemic disease status (p = 0.0003). Systemic disease status had a significant effect on the length of survival but not on the time to recurrence.


This article has been cited by other articles:


Home page
 The OncologistHome page
H.-J. Stemmler and V. Heinemann
Central Nervous System Metastases in HER-2-Overexpressing Metastatic Breast Cancer: A Treatment Challenge
Oncologist, July 1, 2008; 13(7): 739 - 750.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
G. V. Babiera, R. Rao, L. Feng, F. Meric-Bernstam, H. M. Kuerer, S. E. Singletary, K. K. Hunt, M. I. Ross, K. M. Gwyn, B. W. Feig, et al.
Effect of Primary Tumor Extirpation in Breast Cancer Patients Who Present With Stage IV Disease and an Intact Primary Tumor
Ann. Surg. Oncol., June 1, 2006; 13(6): 776 - 782.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. L. Chang and S. Lo
Diagnosis and Management of Central Nervous System Metastases from Breast Cancer
Oncologist, October 1, 2003; 8(5): 398 - 410.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. E. Singletary, G. Walsh, J.-N. Vauthey, S. Curley, R. Sawaya, K. L. Weber, F. Meric, and G. N. Hortobagyi
A Role for Curative Surgery in the Treatment of Selected Patients with Metastatic Breast Cancer
Oncologist, June 1, 2003; 8(3): 241 - 251.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the Society of Surgical Oncology.